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Abstract  52 
 53 
Aims: Bile acids (BAs) are important gut signaling hormones, influencing lipid, glucose, and energy 54 
homeostasis. The exact mechanisms behind these effects are not yet fully understood. Lately, they 55 
have come to the fore as putative therapeutics in metabolic diseases, such as e.g. nonalcoholic fatty 56 
liver disease (NAFLD). We elucidate to what extent BAs impacts on the mRNAome and 57 
microRNAome in hepatocytes to gather novel insights into the mechanisms behind metabolic and 58 
toxicologic effects of bile acids.   59 
Main Methods: Five batches of primary human hepatocytes were treated with 50 μmol/L 60 
chenodeoxycholic acid (CDCA) for 24 or 48 hours. Total RNA was extracted, size fractionated and 61 
subjected to Next Generation Sequencing to generate mRNA and miRNA profiles.   62 
Key findings: Expression of 738 genes and 52 miRNAs were CDCA dependently decreased, whereas 63 
1566 genes and 29 miRNAs were significantly increased in hepatocytes. Distinct gene clusters 64 
controlling BA and lipid homeostasis (FGF(R), APO and FABP family members, HMGCS2) and drug 65 
metabolism (CYP, UGT and SULT family members) were significantly modulated by CDCA. 66 
Importantly, CDCA affected distinct microRNAs, including  miR-34a, -505, -885, -1260 and -552 that 67 
systematically correlated in expression with gene clusters responsible for bile acid, lipid and drug 68 
homeostasis incorporating genes, such as e.g. SLCO1B1, SLC22A7, FGF19, CYP2E1, CYP1A2, APO 69 
family members and FOXO3.   70 
Significance: Bile acids significantly modulate metabolic and drug associated gene networks that are 71 
connected to distinct shifts in the microRNAome These findings give novel insights on how BA 72 
enfold metabolic and system toxic effects.  73 
 74 
 75 
 76 
  77 
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Introduction 78 
Bile acids (BAs) are important endogenous compounds responsible for the efficient absorption of 79 
lipid-soluble compounds in the intestine. Semiquantitative BA derivatives, such as e.g. obeticholic 80 
acid (OCA), are currently discussed as future treatment option for different metabolic diseases, such as 81 
non-alcoholic fatty liver disease (NAFLD), the most common liver disease in the western world [1]. 82 
There is an urgent need to better understand how BAs enfold their effects on metabolic pathways and 83 
on their own homeostasis to better estimate safety and efficacy of these compounds.  84 
The effects of BAs on metabolism are triggered by their interaction with the nuclear receptor FXR, 85 
which leads to improvement of steatosis and fibrosis in NAFLD [1, 2] and a bettering of hepatic 86 
insulin sensitivity [3]. By interacting with FXR, BAs also regulate their own homeostasis via negative 87 
and positive feedback loops [4], thus preventing cells from an intracellular BA overload with toxic 88 
effects [5]. The enterohepatic circulation and homeostasis of BAs are ensured by a coordinated action 89 
of BA uptake and efflux transporters. Bile acid transporters include amongst others the apical sodium-90 
dependent bile acid transporter (ASBT) and organic solute transporters ɑ/β (OSTα/β) in the intestine, 91 
and the Na+-taurocholate co-transporting polypeptide (NTCP), the organic anion-transporting 92 
polypeptides OATP1B1 and OATP1B3 and the bile salt export pump (BSEP)  in hepatocytes [6].   93 
As ligands for the nuclear receptors FXR, PXR or CAR, BAs regulate the expression of several genes 94 
that are important for both BA homeostasis and drug metabolism, such as e.g. OATP1B1, OATP1B3 95 
and CYP3A4. This effect may give space for interactions between BAs and therapeutics and may 96 
affect drug exposure margins with consequences for drug safety and efficacy. By interacting with 97 
several other receptor molecules, besides FXR, such as muscarinic receptors or G protein-coupled 98 
receptors (i.e. TGR5) [7, 8], BAs influence lipid and energy homeostasis. TGR5 triggers weight loss 99 
upon activation by BAs [9-11] and has a positive impact on glucose tolerance by inducing the 100 
secretion of glucagon-like-peptide 1 (GLP-1) from intestinal enteroendocrine cells [12].  101 
Notwithstanding the role of genetic susceptibility factors in the pathogenesis of obesity and diabetes 102 
[13-16], the complex interplay of genetically, epigenetically and microRNA (miRNA)-driven factors 103 
is becoming increasingly evident [17-20]. In particular, shifts in the concentrations of miRNAs, small 104 
noncoding molecules that inhibit mRNA translation, can lead to rapid changes in protein expression 105 
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[21]. MiRNAs belong to a relatively small pool of molecules controlling the expression of major parts 106 
of the genome. Thus, expression changes of only few miRNAs can broadly impact the functional 107 
integrity of different metabolic and signaling pathways.     108 
In the current study we investigate the effect of the BA chenodeoxycholic acid (CDCA) on the 109 
expression of the miRNAome and mRNAome in primary human hepatocytes (PHHs) and assess to 110 
what extent CDCA induces systematic shifts in gene networks responsible for BA and lipid 111 
homeostasis as well as drug metabolism. BA-induced shifts in the miRNA profile are set in context to 112 
the investigated networks to elucidate novel miRNA driven regulatory pathways influencing the 113 
expression of the mentioned gene networks.    114 
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Material and Methods 115 
 116 
Primary human hepatocytes (PHH) 117 
The study was approved by the Ethics Committee of the Canton of Zurich, Switzerland (study number 118 
EK-680) and the Human Tissue and Cell Research (HTCR) Foundation. The HTCR-process that 119 
included written informed consent was approved by the Ethics Committee of the Medical Faculty of 120 
the Ludwig Maximilians University (approval number 025-12) and complied with the Bavarian Data 121 
Protection Act. PHH were obtained from five patients in Germany who were undergoing liver 122 
resection because of liver metastases in association with primary tumors in colon or kidney or because 123 
of hepatocellular carcinoma. The clinical characteristics of the patients are summarized in Table 1 124 
(supplementary information). PHHs were prepared as earlier described [22] and kept in six-well plates 125 
in hepatocyte maintenance medium supplemented with UltraGlutamine for approximately 5 hours 126 
before further treatment procedures. PHHs were cultured at 37°C in a humidified atmosphere 127 
containing 5% CO2 at atmospheric pressure.  128 
 129 
Cell treatment and whole RNA isolation  130 
PHHs of 5 patients were kept in 6 well plates. 24 hours later duplicate wells of each cell batch were 131 
treated with chenodeoxycholic acid (CDCA) or dimethyl sulfoxide (DMSO) (vehicle control)(both 132 
from Sigma-Aldrich, Buchs, Switzerland).. One CDCA and one DMSO treated well of each cell batch 133 
were harvested together 24 hours or 48 hours after cell treatment using TRIzol reagent (Invitrogen, 134 
Carlsbad, CA, USA) for combined DNA and RNA isolation. Subsequently, total RNA was purified 135 
using the miRNeasy kit from Qiagen (QIAGEN, Hombrechtikon, Switzerland).  136 
 137 
Next generation sequencing 138 
For library preparation the quality of the isolated RNA was evaluated using a Qubit® (1.0) 139 
Fluorometer (Life Technologies, Carlsbad, CA, USA) and a Bioanalyzer 2100 (Agilent, Waldbronn, 140 
Germany). Only those samples with a 260 nm/280 nm ratio between 1.8 and 2.1 and a 28S/18S ratio 141 
of 1.5–2 were further processed. 3′ and 5′ RNA adapters were ligated to total RNA samples (1 μg) 142 
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using the TruSeq small RNA Sample Prep Kit v2 (Illumina, Inc., San Diego, CA, USA). Ligated 143 
samples were reverse-transcribed into double-stranded cDNA and fragments containing TruSeq 144 
adapters on both ends were selectively enriched by polymerase chain reaction (PCR). The small RNA 145 
fraction (145–160 bp) was selected and isolated by polyacrylamide gel electrophoresis. The quality 146 
and quantity of the enriched libraries were validated using a Qubit® (1.0) Fluorometer and the Caliper 147 
GX LabChip® GX (Caliper Life Sciences, Inc., Hopkinton, MA, USA). The libraries were diluted to 148 
10 nM in Tris-Cl 10 mM, pH 8.5 with 0.1% Tween 20. For cluster generation and sequencing the 149 
TruSeq PE Cluster Kit v3-cBot-HS was used with 10 pM of pooled normalized libraries on the cBOT 150 
system (Illumina, Inc.). Sequencing was performed on the Illumina HiSeq 2000 using the TruSeq SBS 151 
Kit v3-HS (Illumina, Inc.). 152 
 153 
Processing of NGS data 154 
RNA sequence reads were quality-checked using the software package 155 
fastqc  (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) which computes various quality 156 
metrics for the raw reads. MessengerRNA sequencing reads were aligned to the genome and 157 
transcriptome using the R statistics package tophat v. 1.3.3 with default options. Before mapping, the 158 
low quality ends of the reads were clipped. The fragment length parameter was set to 100 bases with a 159 
standard deviation of 100 bases. Based on these alignments the distribution of the reads across 160 
genomic features was assessed. Isoform expression was quantified using the RSEM algorithm (R 161 
statistics package rsem) [23]. MicroRNA sequencing reads were aligned to the genome and quantified 162 
using ncPro-seq (http://www.ncbi.nlm.nih.gov/pubmed/23044543). 163 
 164 
TaqMan analysis  165 
Messenger RNA quantification was performed by transcribing 1.5 µg mRNA into cDNA using the 166 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Rotkreuz, Switzerland) 167 
according to the manufacturer’s recommendations. cDNA samples were diluted 1:5 and subsequently 168 
used in real-time PCR analyses (RT-PCR) by mixing 2 µl of cDNA and 8 µl of RT-PCR Universal 169 
Fast Master Mix specific to the respective cDNA target (TaqMan® Gene Expression Assays, Life-170 
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Technologies). β-actin was used to normalize measurements. miRNAs were quantified by transcribing 171 
10 ng of extracted RNA into cDNA (TaqMan® miRNA Reverse Transcription Kit, Applied 172 
Biosystems, Rotkreuz, Switzerland) using stem-loop reverse transcription primers specific for the 173 
respective miRNA molecule (TaqMan® MicroRNA Assays, Life Technologies). RT-PCR analyses 174 
were performed using 0.67 µl of cDNA and 9.3 µl of the target-specific RT-PCR Universal Fast 175 
Master Mix (Applied Biosystems). All measurements were performed in triplicate. 176 
 177 
Statistics 178 
Generalized Linear Models (GLM) were used for statistical analysis comparing the mRNA and 179 
miRNA expression values across the different treatment conditions after NGS sequencing. One-180 
sample t-tests were performed to compare the effects of CDCA on the expression of miRNAs versus 181 
DMSO as measured in TaqMan analysis. MiRNAs and mRNAs were correlated by Pearson’s 182 
correlation analyses. Correlation diagrams were obtained using the "corrplot" library of the R-project, 183 
of mRNA and miRNA expression levels in both CDCA and DSMO treated cell lines, respectively. 184 
The statistical packages SPSS 22 and Graphpad Prism version 5 were used for statistical analyses. P 185 
values < 0.05 were considered significant.   186 
  187 
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Results 188 
 189 
Effect of CDCA on genes involved in bile acid synthesis and transport, lipid, retinol and estradiol 190 
metabolism in hepatocytes 191 
PHHs were treated with CDCA or DMSO (empty vehicle) for either 24 or 48 hours to study the effect 192 
on the mRNA and miRNA expression profile. Changes in the expression of mRNAs were in general 193 
more pronounced after 48 hours, and these results are therefore specifically discussed in the following 194 
section. Expression of 738 genes was significantly decreased and expression of 1566 genes was 195 
significantly increased (False Discovery Rate (FDR) in both cases ≤ 46%) after 48 hours of CDCA 196 
treatment. When considering a FDR up to 30%, expression of 432 genes was significantly increased 197 
and expression of 1011 genes was significantly decreased in a BA-dependent manner. Gene 198 
enrichment analysis using the bioinformatics tool Metacore™ (Thomson Reuters) revealed that genes 199 
with altered expression in response to CDCA belong primarily to gene networks involved in BA and 200 
lipid transport and metabolism, as well as estradiol and retinol metabolism (Figure 1). As expected, 201 
CDCA increased expression of FXR-inducible genes such as ABCB11 (BSEP), FGF19, NR0B2 (SHP) 202 
or SLC51A and SLC51B (OSTα, OSTβ) (Table 2).  203 
Genes involved in the regulation of lipid homeostasis that showed altered expression in response to 204 
CDCA included several members of the apolipoprotein (APO) and fatty acid- binding protein (FABP) 205 
family, SLC27A2 and STARD3, as well as genes involved in cholesterol, lipid and fatty acid (FA) 206 
synthesis and metabolism, such as CPT1A, HMGCS2, FASN, ACAT1 and PCSK9 (Table 3). Within 207 
signaling pathways influencing lipid homeostasis, LDLR, PRKCA1, PPARδ, AGPAT2 and SREBF2 208 
were affected by CDCA. However, nuclear receptors known to control both BA and lipid homeostasis, 209 
e.g., FXR and LXR, were not significantly changed in their expression. 210 
 211 
Effect of CDCA on the expression of drug-metabolizing enzymes  212 
As shown in Table 2, CDCA modulated the expression of many genes involved in drug transport and 213 
phase I and II drug metabolism. Among drug-metabolizing cytochrome P450 enzymes, the expression 214 
of CYP2E1, CYP1A1, CYP1A2, CYP2C8, and CYP3A4 was significantly decreased by CDCA. Among 215 
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phase II enzymes, members of the UDP-glucuronosyl-transferase (UGT) and sulfotransferase (SULT) 216 
families in particular showed altered expression in response to CDCA. Specifically, expression of 217 
UGT1A6, 1A7 and 1A9, SULT1E1 and SULT1B1 was decreased and expression of UGT1A1, 2A8 and 218 
2B10, and SULT1C2 was increased by CDCA. Transcription factors that regulate drug metabolism and 219 
excretion, such as the aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR) or 220 
peroxisome proliferator-activated receptor γ (PPARγ) also showed altered expression in response to 221 
CDCA (Table 2). 222 
 223 
The impact of CDCA on the miRNA expression profile in primary human hepatocytes 224 
Whereas only few changes in the miRNA profile were observed after 24 hours’ treatment of PHHs 225 
with CDCA, expression of 52 miRNA molecules was significantly increased and that of 29 miRNAs 226 
was significantly decreased after CDCA treatment for 48 hours, as shown in Table 4 (FDR<0.133, 227 
p<0.01). Results were confirmed by TaqMan analysis remeasuring and confirming the CDCA 228 
dependent downregulation of 3 microRNAs (miR-6503, miR-486 and miR-223) in three separate 229 
hepatocyte batches. These microRNAs belong to the group of miRNA molecules most strongly 230 
affected by CDCA, thus, allowing a confirmatory trend determination in expression by TaqMan 231 
analyses. Other microRNAs affected by CDCA included miR-552, miR-149, and miR-886 (increased) 232 
and miR-34a, miR-30a, miR-452, miR-486 and miR 190a and 190b (decreased). Figures 2 and 3 233 
illustrate the CDCA-dependent miRNA profile as a volcano plot and heatmap, respectively. The 234 
heatmap integrated cluster analysis shows considerable interindividual variability in the miRNA 235 
expression profile following CDCA treatment. 236 
 237 
Correlation of CDCA-induced changes in miRNA levels with mRNA expression  238 
To evaluate the extent to which miRNAs modulated by CDCA could influence the expression of genes 239 
involved in BA synthesis, transport and metabolism, Pearson’s correlation analyses were performed. 240 
Only those miRNAs (shown in Table 4) that were predicted to bind to at least three mRNAs contained 241 
in the gene cluster regulating BA homeostasis (Table 2), lipid metabolism (Table 3) and drug 242 
metabolism (Table 4) were included in the correlation analyses. Binding of miRNAs was predicted 243 
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using the bioinformatics tool mirDIP (http://ophid.utoronto.ca/mirDIP) [24]. As shown in Figure 4  a 244 
distinct cluster of mRNAs consisting of ABCG5 and ABCG8, SLC22A7, NR0B2, SLC51B, SLC10A1, 245 
CYP3A4 and FGF19 is inversely associated with the expression of miR-34a upon CDCA treatment. 246 
The same gene cluster appears to be strongly positively correlated with miRNAs -885, -15b and -505, 247 
leading to the hypothesis that miRNA and mRNA clusters may be regulated by common 248 
transcriptional pathways. As demonstrated in Figure 5, especially microRNA-1260a shows strong 249 
inverse correlations with several important genes involved in lipid homeostasis, including AGPAT2, 250 
S1PR2, CPT1A, APOM, AKR1C1 and LDLR upon CDCA treatment pointing to an inhibitory effect of 251 
miR-1260a on the expression of this gene battery. In contrast to miR-1260a, miRNA-98 that is 252 
strongly inversely correlated with a gene battery including amongst others NPC1L1, HMGCS2, 253 
AGPAT2, FASN, STARD3 and S1PR2l, loses many of those inverse associations upon CDCA 254 
treatment. This observation points to a less strong regulatory impact of miR-98 on the lipid gene 255 
network upon higher hepatic BA concentrations. Figure 6 demonstrates the correlation behavior of 256 
mRNAs belonging to the drug metabolism network and distinct microRNAs. Interestingly miRNA-257 
1260 comes here to the fore again, now with two family members -1260a and -1260b, showing both 258 
strong positive correlations with the drug metabolizing enzymes SULT1E1, CYP1A1 and CYP1A2 and 259 
CYP2E1. Less strong but still relevant positive associations in gene expression are also observed with 260 
the UGT family members UGT2A3, UGT1A7, UGT1A8 and CYP2C8.  This observation suggests a 261 
connection between miR-1260 expression and the expression of the mentioned genes, either through a 262 
common regulatory element of via indirect signaling pathways involving miRNA-1260 as regulatory 263 
compound with impact on e.g. an inhibitory transcription factor regulating the mentioned gene battery.   264 
 265 
 266 
 267 
  268 
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Discussion 269 
 270 
We systematically investigated the effect of CDCA on the mRNAome and miRNAome in human 271 
hepatocytes. Using CDCA as a model substance we demonstrate that BAs have the ability to 272 
profoundly change the transcriptional pattern of gene networks involved in BA and lipid homeostasis, 273 
as well as drug metabolism and disposition. These results together with our observation that distinct 274 
microRNAs appear to be bile acid dependently changed in expression provide important novel insights 275 
into the regulatory mechanisms behind systematic effects of BAs that are of both liver therapeutic and 276 
toxicological relevance. 277 
CDCA had both enhancing and suppressing effects on the expression of miRNAs, with the majority of 278 
the miRNA molecules having decreased levels under CDCA treatment. Importantly, we show that 279 
CDCA modulates the expression of distinct miRNAs that appear to be connected to the expression of 280 
gene clusters within the bile acid, lipid and drug homeostasis associated gene networks. MicroRNA-281 
34a is CDCA dependently and strongly inversely correlated with key genes involved in BA 282 
homeostasis including FGF19, NR0B2 (SHP), OSTα/β, ABCG5/ABCG8, and SLC22A7. This finding 283 
suggests a key role of miR-34a in the autoregulation of bile acid homeostasis. We observed a strong 284 
downregulation of  miR-34a, which is well in line with results published by Castro et al. (2013), 285 
showing a suppressive effect of ursodeoxycholic acid in patients suffering from NAFLD [25]. The 286 
suppressive effect of CDCA on miR-34a expression suggests also consequences for NAFLD 287 
development, and the regulation of energy homeostasis and cancer related pathways. MicroRNA-34a 288 
has been shown to SIRT-dependently regulate brown fat formation. The observed upregulation of 289 
serum miR-34a in NAFLD patients underlines the importance of miR-34a in metabolic diseases [26]. 290 
MiRNA-34a has been studied in the context of cancer development and tumor growth. Associations 291 
with disease development, prognosis and severity have been described for bladder, breast, liver and 292 
colon cancer as well as lymphoma [27-30]. Besides miR-34a, we detected a distinct microRNA 293 
cluster, composed of miR-885, miR-505 and miR-15b, to be CDCA dependently modulated in 294 
expression. These microRNAs were significantly upregulated and showed, in contrast to miR-34a - a 295 
positive correlation with the group of genes inversely associated with the expression of miR-34a. It is 296 
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conceivable that these three miRNAs and the associated BA gene cluster are co-regulated by a 297 
common transcriptional pathway that is activated by CDCA. MiRNA-885 has been shown to play a 298 
role in the pathogenesis of different cancer types [31, 32] and has also been discussed as a potential 299 
serum marker for the detection of ongoing liver pathologies [33]. MiR-15b has been shown to be up-300 
regulated in NAFLD, and thus, has been suggested to play a role in the pathogenesis of this disease 301 
[34]. MicroRNA-505-3p is discussed as putative biomarker for primary biliary cirrhosis [35].  302 
CDCA strongly affected genes involved in lipid homeostasis, including FGF2, FGFR2, HMGCS2, 303 
FABP and APO family members. As potent ligands for FXR, CDCA and other BAs regulate genes 304 
involved in cholesterol, FA, and lipid metabolism, either by direct transcriptional activation or by 305 
FGF-dependent hormonal signaling. In vivo studies performed in mice have shown that orally 306 
administered BAs lead to a positive effect on body weight [36] and lower the risk for NAFLD under 307 
high-fat diet conditions [2]. Our results support the notion that BAs modulate the expression pattern of 308 
genes involved in lipid synthesis, transport and metabolism, which could contribute to the lipid 309 
lowering properties repeatedly observed with BAs. In this context we would like to highlight the 310 
enhancement of miR-1260 expression upon CDCA treatment, which was associated with a strong 311 
parallel expression of genes involved in xenobiotica metabolism (CYP2E1, CYP1A1, CYP1A2) and 312 
an inverse expression of important genes involved in lipid homeostasis (i.e. CPT1A, APOM, LDLR). 313 
This finding points to a putative coregulatory element regulating the expression of miR-1260 and the 314 
mentioned drug gene group and a role of this microRNA as regulatory element in lipid metabolism. 315 
MicroRNA-1260 has been recently described as putative biomarker for paclitaxel-induced apoptosis in 316 
HCC cells [37]. Our systematic analysis of genes involved in drug metabolism and transport show, 317 
that many genes belonging to phase I (CYP1A members, CYP2E1, CYP2C8), phase II (several genes 318 
of the UGT and SULT family) and phase III (SLC22A1, SLC22A7) are significantly modulated by 319 
CDCA. This observation allows the speculation that bile acid derivates may have the potential to 320 
induce drug-drug interactions with other compounds through the modulation of DM gene expression. 321 
The importance of our findings with regard to a relevant interplay of BAs and DMEs is further 322 
underlined by the fact that distinct and relevant drug-drug interactions with BAs have been earlier 323 
described in other studies. This comprises amongst others the interaction between the 324 
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immunosuppressant  Ciclosporine A and bile acids. Ciclosporine A has been demonstrated to lead to a 325 
significant accumulation of bile acids and the development of a cholestatic feature in liver derived 326 
HepaRG cells [38]. Another important example comprises the interaction of the calcium channel 327 
blocker nitrendipine and CDCA. Sasaki and co-workers demonstrated that CDCA and UDCA are able 328 
to inhibit nitrendipine absorption by 50% and thus to decrease plasma concentrations of nitrendipine to 329 
a clinically relevant extent in healthy individuals [39].  330 
Because the five batches of PHHs were obtained from patients resected for liver metastases that were 331 
incurred through different malignant tumors such as colon or kidney cancer, it cannot be excluded that 332 
the underlying pathologies or the existence of genetic polymorphisms within the discussed gene 333 
clusters or in genes coding for key transcription factors could induce an additional variance in gene 334 
expression. We specifically concentrated on the question to what extent CDCA is able to change the 335 
microRNA profile, as also optimally measurable in the chosen time frame of 48 hours. It would be 336 
interesting to further study in future studies how and to what extent other epigenetic regulatory 337 
mechanisms, such as e.g. methylation or histone acetylation, are influenced by CDCA. Correlation 338 
analyses were done at the miRNA/mRNA level. Because the regulatory effect of miRNAs is often 339 
only observed at the protein level, we cannot exclude the possibility that the miRNAs have additional 340 
effects on targets that were not detected by assessment of mRNA levels alone.  341 
We conclude that the expression of the human miRNAome and mRNAome in PHHs are significantly 342 
modulated by the bile acid CDCA, with relevant consequences for the functionality of gene networks 343 
involved in bile acid, lipid and drug metabolism. CDCA-induced regulation by miRNAs may exert 344 
downstream effects on genes within functionally important networks. Our findings give important 345 
novel insights into the ability of BA derivates to induce relevant changes in gene networks relevant for 346 
BA compound safety and metabolic disease development such as obesity and NALFD. 347 
  348 
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Fig. 1 Gene enrichment analysis showing signaling pathways most affected by CDCA 556 
 557 
Fig. 2 Effect of CDCA on the global miRNA profile in five batches of primary human 558 
hepatocytes. Dots represent the average fold-change of miRNAs shown as log2 values (x-axis) and 559 
corresponding p values represented as –log10 values (y-axis) when comparing CDCA and empty 560 
vehicle (DMSO) treated cells. Red: miRNAs with p values <0.01. Yellow: miRNAs with p values 561 
<0.05. Green: miRNAs with p values >0.05. Labeled miRNAs represent molecules that showed a ≥ 562 
2fold increase or decrease.   563 
 564 
Fig. 3 Heat map showing CDCA-induced changes in miRNA profile clustering in five batches of 565 
primary human hepatocytes. MiRNAs with changes of at least 50% and p values <0.05 are shown. 566 
Red: increased miRNAs. Green: decreased miRNAs.  567 
 568 
Fig. 4 Pearson’s Correlation analyses on mRNA and miRNA expression levels taking genes from 569 
the BA gene cluster into consideration. DMSO treatment (A), CDCA treatment (B). MicroRNAs 570 
with predicted binding sites in at least three target genes within the bile acid (BA) gene cluster and 571 
significantly up- or downregulated (FDR ≤ 0.133) were included. Shown are BA mRNA targets that 572 
were significantly up or down regulated by CDCA (FDR < 0.46). blue, positive correlation; red, 573 
inverse correlation. A distinct gene cluster composed of important BA homeostasis regulating genes, 574 
comprising SLC51A, CYP3A4, SLC22A7, NR0B2, ABCG5/8, SLC51B, FGF19 and SLC10A1 appears 575 
to be strongly inversely correlated with miRNA-34a and positively correlated with the microRNAs 576 
miR-885, miR-15b, and miR-505 upon CDCA treatment (highlighted in green). 577 
 578 
Fig. 5 Pearson’s Correlation analyses on mRNA and miRNA expression levels taking genes from 579 
the lipid gene cluster into consideration. DMSO treatment (A), CDCA treatment (B). Analyses 580 
included miRNAs significantly up or downregulated and with predicted binding sites in at least three 581 
target genes within the lipid gene cluster. Shown are lipid cluster mRNA targets significantly up or 582 
down regulated. Blue, positive correlation; red, inverse correlation. A distinct gene cluster composed 583 
22 
 
of important lipid homeostasis regulating genes, such as S1PR2, CPT1A, APOM, AKR1C1 and 584 
LDLR is strongly inversely correlated with the expression of miR-1260a upon CDCA treatment 585 
(highlighted in green). 586 
 587 
Fig. 6 Pearson’s Correlation analyses on mRNA and miRNA expression levels taking genes from 588 
the DM gene cluster into consideration. DMSO treatment (A), CDCA treatment (B). Analyses were 589 
performed including those miRNAs that were significantly up or downregulated and for which binding 590 
sites in at least three target genes within the drug transport and metabolism (DM) gene cluster were 591 
predicted. Shown are DM mRNA targets that were significantly up or down regulated. blue, positive 592 
correlation; red, inverse correlation. A distinct gene battery, composed of important genes encoding 593 
drug metabolizing enzymes, including SULT1E1, CYP1A2, CYP1A1 and CYP2E1 and to a less 594 
extent several UGT family members and CYP2C8, is positively correlated with the expression of miR-595 
1260a and miR-1260b upon CDCA treatment (highlighted in green). 596 
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  600 
Fig. 5 
DMSO treatment (48 hours)       CDCA treatment (48 hours) A B 
Fig 4 
DMSO treatment (48 hours)   CDCA treatment (48 hours) B A 
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  601 
Fig 6 
DMSO treatment (48 hours)   CDCA treatment (48 hours) A B 
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Table 1: Clinical characteristics of liver cell donors 602 
Patient No Gender Age Main diagnosis drugs 
1 female Between 71 
and 80 
colon carcinoma and 
liver metastases 
none 
2 female Between 70 
and 79 
GIST tumor none 
3 female Between 51 
and 60 
rectosigmoid carcinoma 
with liver metastases 
state after 6 cycles of 
Oxaplatin/folinic acid 
(FUFOX) 
avastatin 
4 female Between 51 
and 60 
liver metastasis  after 
kidney cancer  
bisoprolole 
L-thyroxine 
zopiclone 
anagrelide 
5 female Between 31 
and 40 
Hepatocellular 
carcinoma 
metamizole 
 603 
 604 
 605 
 606 
Supplemental Table S1 to S6.  Correlation coefficients obtained performing Pearson’s correlation 607 
analyses of significantly upregulated and downregulated miRNAs and mRNAs belonging to the bile 608 
acid, lipid and drug metabolism network (exact quantitative outcome in accordance to figure 3 to 5). 609 
MRNAs and miRNAs are listed in alphabetical order on the x and y axis. 610 
 611 
 612 
 613 
 614 
 615 
 616 
 617 
 618 
 619 
 620 
 621 
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 622 
Table 2 Effect of CDCA on the expression of genes involved in bile acid homeostasis and drug 623 
metabolism in primary human hepatocytes after 48 hours  624 
*Genes involved in drug metabolism or bile acid homeostasis with a FDR < 0. 46 a p-value < 0.05 625 
**involved in both bile acid homeostasis and drug metabolism or drug transport 626 
Gene name* log2 Ratio Fold change p value FDR 
up-regulated genes 
Bile acid homeostasis 
FGF19 5.078 33.78 3.541xE-07 9.624xE-05 
SLC51B 4.934 30.57 1.091xE-15 2.958xE-12 
NR0B2 2.85 7.21 9.207xE-11 8.158xE-08 
ABCB11 2.195 4.58 2.194xE-09 1.177xE-06 
SLC51A 2.194 4.58 8.15xE-16 2.768xE-12 
ABCB4 1.603 3.04 5.099xE-10 3.149xE-07 
ABCG5 0.8736 1.83 0.0015 0.065 
SLCO1B3** 0.5981 1.51 0.0045 0.124 
ABCG8 0.4935 1.41 0.0438 0.434 
Drug metabolism 
UGT2B10 1.264 2.4 0.0006 0.033 
SULT1C2 1.13 2.19 0.0393 0.412 
UGT1A8 0.9499 1.93 0.021 0.298 
UGT2B4 0.7462 1.68 0.0098 0.196 
UGT1A3 0.5976 1.51 0.0269 0.34 
UGT1A1 0.5671 1.48 0.0416 0.425 
PPARG 0.5001 1.41 0.0431 0.432 
down-regulated genes 
Bile acid homeostasis 
EPHX1** -0.4618 0.73 0.035 0.389 
NR1I3 -0.5675 0.67 0.0106 0.207 
SLCO1B1 -0.5869 0.67 0.0046 0.126 
BAAT -0.8562 0.55 0.0035 0.107 
CYP3A4** -1.734 0.3 2.055xE-13 3.49xE-10 
CYP7A1 -6.271 0.01 9.197xE-18 4.686xE-14 
Drug metabolism 
AHR -0.4569 0.73 0.0413 0.423 
UGT1A6 -0.5588 0.68 0.0127 0.229 
NR1I3 -0.5675 0.67 0.0106 0.207 
SLCO1B1 -0.5869 0.67 0.0046 0.126 
UGT2A3 -0.7303 0.6 0.0026 0.09 
SULT1B1 -0.7455 0.6 0.0017 0.067 
UGT1A7 -0.9585 0.51 0.0423 0.429 
SLC22A7 -1.054 0.48 0.0189 0.282 
CYP2C8 -1.605 0.33 8.14E-07 <0.001 
SULT1E1 -1.679 0.31 0.0014 0.063 
SLC22A1 -1.726 0.3 8.55E-12 1.09E-08 
CYP1A2 -1.921 0.26 1.05E-07 3.23E-05 
CYP1A1 -1.954 0.26 1.96E-05 0.002 
UGT1A9 -2.095 0.23 6.84E-05 0.007 
CYP2E1 -2.556 0.17 2.03E-21 2.07E-17 
29 
 
 627 
Table 3 Effect of CDCA on the expression of genes involved in lipid homeostasis in primary human 628 
hepatocytes after 48 hours  629 
 630 
Gene name* log2 ratio Fold Change p value FDR 
Bile acid dependently up-regulated genes 
FABP3 2.981 7.9 0.0001 0.009 
APOL3 1.464 2.76 1.50E-10 1.09E-07 
FGFR2 1.42 2.68 8.02E-06 0.001 
LDLR 1.339 2.53 4.20E-13 6.58E-10 
PPARD 1.256 2.39 2.18E-06 <0.001 
FGF21 1.25 2.38 0.0281 0.347 
FASN 1.185 2.27 0.0081 0.174 
PCSK9 1.182 2.27 3.95E-06 0.001 
S1PR2 1.146 2.21 0.0122 0.224 
S1PR1 0.9341 1.91 2.49E-05 0.003 
PRKCE 0.8938 1.86 0.0019 0.073 
APOA2 0.8007 1.74 0.003 0.098 
SCARB1 0.691 1.61 0.0017 0.068 
CPT1A 0.6706 1.59 0.0018 0.071 
SREBF2 0.6289 1.55 0.0071 0.162 
LDLRAP1 0.6005 1.52 0.0061 0.149 
NPC1 0.5843 1.5 0.0024 0.085 
NPC1L1 0.5734 1.49 0.0014 0.061 
SLC27A2 0.5539 1.47 0.0034 0.106 
STARD3 0.5293 1.44 0.02643 0.336 
FGF2 0.526 1.44 0.02203 0.305 
PRKCA 0.5093 1.42 0.0053 0.137 
FOXO3 0.5087 1.42 0.0284 0.349 
AGPAT2 0.5037 1.42 0.0187 0.281 
CREBBP 0.45 1.37 0.0355 0.391 
FGFRL1 0.4191 1.34 0.0493 0.459 
ATF6B 0.416 1.33 0.0352 0.389 
Bile acid dependently down-regulated genes 
ACAT1 -0.432 0.74 0.02 0.291 
PEX3 -0.4953 0.71 0.0115 0.216 
AKR7A3 -0.5941 0.66 0.0041 0.118 
APOM -0.6031 0.66 0.0064 0.151 
ACADSB -0.6303 0.65 0.0008 0.042 
APOC4 -0.7548 0.59 0.0086 0.182 
AKR1C1 -0.8871 0.54 0.0161 0.261 
APOH -0.9548 0.52 0.0004 0.027 
ANGPTL3 -0.9995 0.5 0.0009 0.045 
ACAD11 -0.9997 0.5 2.95E-07 8.36E-05 
APOA4 -1.059 0.48 0.0135 0.239 
AKR1C4 -1.069 0.48 7.84E-08 2.66E-05 
FABP7 -1.964 0.26 0.0051 0.134 
HMGCS2 -2.128 0.23 0.0001 0.01 
  * Genes involved in lipid homeostasis (FDR < 0. 46 and p-value < 0.05) 631 
  632 
30 
 
Table 4  Effect of CDCA on the expression of miRNAs in primary human hepatocytes after 48 hours  633 
 634 
miRNA* log2 ratio Fold Change p value FDR 
Bile acid dependently up-regulated miRNAs 
hsa-mir-552 1.588 3.006 0.0073 0.126 
hsa-mir-1260a 1.243 2.367 <0.0001 0.002 
hsa-mir-149 1.207 2.309 0.0052 0.115 
hsa-mir-1260b 1.186 2.275 <0.0001 0.004 
hsa-mir-3651 1.129 2.187 0.0032 0.115 
hsa-mir-4485 0.9179 1.889 0.0038 0.115 
hsa-mir-3607 0.8542 1.808 0.0043 0.115 
hsa-mir-505 0.8398 1.79 0.0035 0.115 
hsa-mir-6723 0.7282 1.657 0.0052 0.115 
hsa-mir-15b 0.7139 1.64 0.0036 0.115 
hsa-mir-328 0.7 1.625 0.0081 0.133 
hsa-mir-92a-2 0.6913 1.615 0.0091 0.133 
hsa-mir-204 0.5362 1.45 0.0092 0.133 
hsa-mir-885 0.4937 1.408 0.0097 0.133 
Bile acid dependently down-regulated miRNAs 
hsa-mir-34a -0.44 0.737 0.0087 0.133 
hsa-mir-30a -0.5096 0.702 0.0055 0.116 
hsa-mir-98 -0.6309 0.646 0.0062 0.122 
hsa-mir-5590 -0.8854 0.541 0.0036 0.115 
hsa-mir-2355 -0.9401 0.521 <0.0001 0.004 
hsa-mir-190a -1.1 0.467 0.0022 0.115 
hsa-mir-190b -1.266 0.416 0.0096 0.133 
hsa-mir-2467 -1.421 0.373 0.0038 0.115 
hsa-mir-2114 -1.653 0.318 0.005 0.115 
hsa-mir-452 -1.847 0.278 <0.0001 0.002 
hsa-mir-486 -2.285 0.205 0.0047 0.115 
hsa-mir-486-2 -2.287 0.205 0.0048 0.115 
hsa-mir-451b -2.461 0.182 0.0069 0.125 
hsa-mir-451a -2.461 0.182 0.0069 0.125 
hsa-mir-6503 -2.9 0.134 0.0009 0.073 
*Shown are all CDCA dependently modulated microRNAs with a FDR ≤ 0.133 and a p-value < 0.01 635 
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